We're on a mission to cure Peyronie's disease

Please Accept Our Sincere Apologies

Our company, its research, and our intellectual property is self-funded by stakeholders and from profits derived from our urologic services. We are a small group of doctors, scientists, and clinicians with just one focus: developing a cure for Peyronie's disease.

Unfortunately, there's much more to it when it comes to actually delivering breakthrough technology to patients and getting those services covered by insurance. Our hands will be tied for at least another twelve months as we create enough added value through new drug patents for our future Pharma partner to fund the $50 million costs that will be associated with getting all clearances, universal insurance coverages, and worldwide distribution for all of our breakthroughs.

If you're a patient or clinician who's reached out wanting additional information on our breakthroughs to date, we sincerely apologize for our inability to be responsive. Like many early stage Biomed enterprises, we're somewhat understaffed, overworked, underpaid, and legally limited in terms of what we can share publicly at this moment.

Apology to Clinicians: We are currently navigating the creation of new drugs in tandem with our novel drug delivery system and patient protocols. Unfortunately at this point, we cannot share anything about what we're doing with anyone, and we can't make our technologies available for testing yet. Nor can we publish our exciting insights and outcomes in clinical journals.

All the pieces are intertwined with the patents, which are key for us getting funding to make all this universally available. We've been advised this "lock up" period will likely come to an end within the next twelve to eighteen months. We're on pins and needles waiting to help you better serve Peyronie's patients.

Apology to Peyronie's Patients: We are working around the clock to deliver on our curative vision for one reason: to help the growing number of men who are so horribly afflicted by Peyronie's Disease. Unfortunately, our hands will be tied for another 12-18 months as we create added value to attract the $50 million in costs required for all the clearances, universal insurance coverages, and technology distribution.

When it comes to patients, possibly the three most heartbreaking parts of what we do are:

1. Seeing men fall for the endless array of fraudulent Peyronie's Disease "cures". Right now, P-shot derivatives and the endless array of acoustic wave therapies are most likely the worst offenders—borderline criminal, in our opinion. Over the past 20 years, we have seen a great deal more of them.
2. Witnessing well-meaning patients and even healthcare professionals provide Peyronie's patients incorrect advice, usually via online forums. We're not allowed to interject and provide better guidance, which is difficult at times given all we now understand about the uniqueness of each Peyronie's case.
3. Reading heartbreaking posts on the vulnerable mental and physical states of so many men with Peyronie's disease. Some of these have been prominently displayed in our lab as a constant reminder of the significance of everyone's work.

Our institute is focused on finding a cure for Peyronie’s Disease.

• We unlocked the underlying epidemiology of Peyronie's Disease.
• Our research uncovered six "Peyronie's Accelerators", and in order to successfully heal this disease, they must be controlled and optimized. Along with the scope and size of fibrous plaques, these factors are usually the root cause of why some men succeed with certain therapeutics while others do not.
• Our patented therapeutics combining pulsated gas injections just before injection of intralesional drugs opens small pathways for medicines to become effective, which breaks down Peyronie's fibrosis without surgery.
• The factors of a Peyronie's case, including plaque size, density, and position, as well as the state of each Peyronie's Accelerator and a calculated health factor rating, are all taken into consideration by our unique therapeutic algorithm. Continued refinements to this algorithm will be crucial for rapid training of urologists around the globe in the future.
• Earlier in the development of our Peyronie's technology, we sometimes couldn't get the penis back to its original size after removing Peyronie's plaques. Thus, we developed novel methods for cosmetic urology (penis augmentation). Since then, we uncovered the secret to regaining lost size from Peyronie's Disease during our therapeutic treatments. However, our platform for cosmetic urology—headed by renowned reconstructive urologist Kenneth J. Carney, MD, PHARM, FACS—has enjoyed notable success. A primary source of funding for our Peyronie's cure research has come from our cosmetic urology platform.
• We are currently developing technologies that will leverage improved treatment methods and novel drugs to expedite the progression of obstinate Peyronie's cases. We've started talks to collaborate with a global pharmaceutical company to finance our FDA approvals and make sure the revolutionary ExoSurge technology becomes available globally in the upcoming years.

1. ExoSurge is a curative therapeutic treatment that includes a novel drug delivery Medtech device where injected pulsated gas destalizises fibrous Peyronie's plaques enough where injected intralesional drugs can slowly dissolve Peyronie's fibrosis. We've succeeded removing fibrous plaques using generic drugs but we're experimenting with new medicines that will hopefully speed up the plaque dissolution processs.
2. ExoSurge is a detailed protocol customized based upon a wide variety of variations in patient disease factors and personal health dynamics. These factors are crucial to include in the treatment plan for every Peyronie's case to ensure fibrotic removal.
3. ExoSurge requires patient management and patient responsibility managing discovered metrics we call “Peyronie’s Accelerators”. If these metrics remain elevated during treatments, improvement is severely compromised.

To learn more about about how we believe ExoSurge® IPG is positioned to revolutionize Peyronie's Disease care, click below.

ExoSurge® is the world's first clinically-proven treatment to conservatively and permanently remove plaques and fibrosis associated with a Peyronie's diagnosis.

The following are verified patient reviews. Our clinic has supporting documentation. Edits have occasionally been made to correct grammatical or spelling errors.